Purpose: Prostate cancer commonly metastasises to bones, lymph nodes or lungs. Skin metastases are exceedingly rare, with only 0.06-0.3% of metastatic prostate cancer cases. The clinical presentation of cutaneous metastases often mimics benign dermatological lesions, leading to diagnostic challenges and delays in appropriate management. Case: An 83-year-old gentleman with high volume Gleason 5+5 metastatic prostate adenocarcinoma, managed with leuprorelin, darolutamide and docetaxel, presented to his GP with multiple erythematous papulonodular lesions on his face four months after diagnosis. These lesions were painless but bled on contact, raising suspicion for recurrence of malignant melanoma. Excision biopsy revealed adenocarcinoma, staining positive for NKX3 as well as PSA on immunohistochemistry, suggestive of metastatic prostate adenocarcinoma. The patient subsequently developed rapid recurrence of these lesions in his forehead, face, scalp and back. He received palliative radiation therapy (18Gy) for symptomatic management with good effect. Discussion: Cutaneous metastasis of prostate cancer is rare and often is associated with widespread metastasis and poor prognosis. Most common sites reported in the literature are lower abdomen and pelvis, perineum and genital area. Distant sites like the face and scalp are exceedingly rare and indicate advanced systemic disease. Whilst most lesions are firm painless nodules, some can ulcerate or become inflamed impacting quality of life. Management of these lesions are largely palliative with excision and radiation therapy being most commonly described.